Work

Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy

Year: 2020
Type: review
Abstract: Until recently, there was no approved treatment for a retinal degenerative disease. Subretinal injection of a recombinant adeno-associated virus (AAV) delivering the normal copy of the human RPE65 cDNA led to reversal of blindness first in animal models and then in humans. This led to the first US Food and Drug Administration (FDA)-approved gene therapy product for a genetic disease, voretigene neparvovec-rzyl (Luxturna). Luxturna was then approved by the European Medicines Association and is now available in the US through Spark Therapeutics and worldwide through Novartis. Not only has treatment with Luxturna changed the lives of people previously destined to live a life of blindness, but it has fueled interest in developing additional gene therapy reagents targeting numerous other genetic forms of inherited retinal disease. This review describes many of the considerations for administration of Luxturna and describes how lessons from experience with Luxturna could lead to additional gene-based treatments of blindness.
Language: English
Subfield: Ophthalmology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,500
OpenAlex ID: W3107549158
FWCI: 3.455
Cites: 194
Cited by: 197
Related to: 10